Mark de Souza

Part of Groupe Limagrain Holding SA, Biotechnica International, Inc. is a company that specializes in agricultural research. The company is based in Shawnee Mission, KS.

Part of Celldex Therapeutics, Inc., Virus Research Institute, Inc. develops systems for the delivery of vaccines. The company is based in Cambridge, MA.

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company, which develops and markets Levulan Photodynamic Therapy technology platform for the prevention and treatment of dermatological skin conditions. Its products include levulan kerastick, BLU-U and clindareach. The company was founded by D. Geoffrey Shulman on February 21, 1991 and is headquartered in Wilmington, MA.

Soros Fund Management LLC (SFM) is a privately-held investment management firm now structured as a family office, but which was once a hedge fund manager. The firm was founded in 1969 and is headquartered in New York City. SFM serves as the principal asset manager for the Open Society Foundations (Open Society) – a private funder of independent groups that works for justice, democratic governance, and human rights.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

VelQuest Corp. provides integrated compliance management solutions. The company's software is used by pharmaceutical companies to reduce compliance risk, liberate valuable resources and add value to existing document management and IT resources. Its SmartLab GMP Electronic Notebook System is built on electronic process management and compliance core operating system to provide the foundation for compliance based activities in the life science markets. The firm's services include planning and consulting, implementation, validation, customer education, field Service and customer support. VelQuest was founded in January, 1999 and is headquartered in San Diego, CA.

Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA.

PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Lazard Asset Management LLC (LAM) is a SEC-registered investment advisor headquartered in New York City. The firm was founded in 1970 and is a wholly-owned subsidiary of Lazard Frères & Co. LLC, ultimately held by Lazard, Inc. (NYSE: LAZ). LAM manages investment portfolios and provides investment advice to institutional and individual investors around the world.

EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA.

Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

MEDNA Partners LLC private advisory firm. The company is headquartered in Cambridge, MA.

Darwin Ventures LLC (Darwin Ventures) is a venture capital founded in 2002 by Peter Freudenthal and Frank R. Caufield. The firm is headquartered in Burlingame, California.

Lotus Tissue Repair, Inc. develops dermatologic treatment technologies. Its solutions include a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a group of genetic skin disease. The company was founded by Mei Chen, Mark P. de Souza, Philip R. Reilly, David Woodley and James W. Fordyce in 2011 and is headquartered in Lexington, MA.

Valerion Therapeutics LLC develops targeted therapies for orphan genetic diseases. The firm utilizes a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a studied transport pathway. It therapies are based on an intracellular delivery technology platform that takes advantage of tissue targeting via an antibody and intracellular delivery dependent on membrane expression of a nucleoside transporter. The company was founded by Timothy S. Harris and Dustin D. Armstrong in 2007 and is headquartered in Concord, MA.

Alopexx Enterprises LLC engages in investing and managing health care companies. It develops medical therapies and devices for infectious diseases, oncology, central nervous system, and orphan diseases. The firm commercializes an alternative for the treatment and prevention of staphylococcal and other bacterial infections and animal vaccines. The company was founded by Daniel R. Vlock, Deborah Ramsdell and Christine de los Reyes in 2011 and is headquartered in Concord, MA.

EB Research Partnership operates as a foundation for the research and treatment of Epidermolysis Bullosa. The company was founded by Alexander Silver, Jill Vedder, Ryan Fullmer, Jamie Silver and Heather Fullmer and is headquartered in New York, NY.

Orphan Technologies Ltd. engages in the manufacturing of biopharmaceutical drugs. It develops novel therapies for patients suffering from rare disorder and classical homocystinuria. The company is headquartered in Rapperswil, Switzerland.

3CC Management LLC (Third Culture Capital) is a venture capital firm founded in 2020 by Julien L. Pham. The firm is headquartered in Boston, Massachusetts.

SeylanMED, Inc. engages in the development of topical akt inhibitor as a treatment for seborrheic keratosis. The company was founded by Victor Neel and Anna Mandinova and is headquartered in Berkeley, CA.

NF2 Therapeutics, Inc. develops therapies. The American company was founded by Michael Wootton, Mark P de Souza, Scott Plotkin. Michael Wootton has been the CEO since incorporation.